15-Year watch begins for gene therapy recipients
NCT ID NCT06882317
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 40 people who previously received CLBR001, a gene-modified cell therapy, to monitor long-term safety over 15 years. No new treatment is given. Researchers will track side effects and check for any lingering virus from the gene therapy. The goal is to understand delayed risks, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CLBR001 (a gene-modified immune cell therapy)
- What this could lead to
- If successful, this study will provide crucial safety data on gene-modified cell therapies, helping to guide future treatments.
- What could go wrong
- This is an observational follow-up study, not a treatment trial. It cannot prove the therapy works or is safe for new patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG TERM FOLLOW-UP are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
-
University of Virginia
Charlottesville, Virginia, 22908, United States
-
Virtual Research Group- Premier Research
Morrisville, North Carolina, 27560, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.